

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**SECOND QUARTER**  
**2004**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	2Q '04 vs. 2Q '03					
	TOTAL % CHG <sup>(1)</sup>	TOTAL \$	U.S. % CHG <sup>(1)</sup>	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-17%	21	*	-	9%	21
ARCOXIA	*	62	-	-	*	62
CANCIDAS	65%	101	64%	58	66%	43
COZAAR / HYZAAR	34%	725	70%	259	20%	466
CRIXIVAN / STOCRIN	-21%	64	-75%	6	2%	58
EMEND	-39%	9	-42%	8	*	1
FOSAMAX	45%	792	58%	438	32%	354
INVANZ	86%	16	69%	11	*	4
MAXALT	56%	79	87%	51	20%	28
PRIMAXIN	5%	153	12%	36	3%	117
PROPECIA	28%	65	54%	32	10%	33
PROSCAR	2%	185	-1%	95	6%	90
SINGULAIR	52%	643	67%	453	26%	189
TIMOPTIC / TIMOPTIC XE	-10%	39	-60%	2	-2%	36
TRUSOPT / COSOPT	8%	133	12%	58	6%	75
VASOTEC / VASERETIC	-3%	195	*	-	-5%	195
VIOXX	-18%	653	-35%	357	20%	296
ZOCOR	12%	1,370	27%	958	-11%	411
HEPATITIS VACCINES	-18%	43	-27%	31	22%	11
VIRAL VACCINES	1%	135	-1%	124	19%	11
OTHER VACCINES	-9%	46	-13%	34	5%	12

\* 100% or over

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	2Q '04	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	<u>\$ 6,022</u>	<u>9%</u>	<u>5</u>	<u>1</u>	<u>3</u>
U.S. (\$ MM)	3,454	7%	4	3	0
Foreign (\$ MM)	2,567	11%	7	-3	7

<sup>(1)</sup> Sales growth for the quarter includes a favorable comparison to 2003, which was impacted by \$405 million of wholesaler buy-out. Following the implementation of the new distribution program for U.S. wholesalers in the fourth quarter of 2003, fluctuations in 2004 sales caused by wholesaler investment buying have significantly moderated.

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**YEAR-TO-DATE**  
**2004**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	JUNE YTD `04 vs. JUNE YTD `03					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-10%	44	*	-	12%	44
ARCOXIA	*	92	-	-	*	92
CANCIDAS	75%	189	72%	107	79%	82
COZAAR / HYZAAR	15%	1,354	8%	475	20%	879
CRIXIVAN / STOCRIN	-22%	129	-81%	12	14%	116
EMEND	4%	15	-2%	14	*	1
FOSAMAX	16%	1,551	4%	880	35%	671
INVANZ	94%	27	72%	20	*	8
MAXALT	5%	135	-6%	80	25%	54
PRIMAXIN	-2%	303	-31%	65	11%	238
PROPECIA	10%	128	8%	61	12%	67
PROSCAR	15%	359	17%	178	14%	181
SINGULAIR	43%	1,266	46%	880	36%	385
TIMOPTIC / TIMOPTIC XE	-3%	76	-34%	5	0%	71
TRUSOPT / COSOPT	16%	264	15%	110	17%	155
VASOTEC / VASERETIC	0%	367	*	-	-2%	367
VIOXX	0%	1,314	-13%	743	25%	571
ZOCOR	11%	2,665	33%	1,858	-19%	807
HEPATITIS VACCINES	-12%	103	-14%	84	-3%	19
VIRAL VACCINES	0%	252	-2%	229	28%	23
OTHER VACCINES	-10%	98	-14%	74	2%	24

\* 100% or over

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	YTD `04	% CHG.	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	<b>\$ 11,653</b>	<b>5%</b>	<b>0</b>	<b>1</b>	<b>4</b>
U.S. (\$ MM)	6,710	1%	-2	3	0
Foreign (\$ MM)	4,943	11%	4	-3	10

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**SECOND QUARTER**  
**2004**

**OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (millions of dollars)**

	2Q `04	2Q `03	YTD 2004	YTD 2003
INTEREST INCOME	\$ (68.5)	\$ (82.2)	\$ (134.2)	\$ (169.6)
INTEREST EXPENSE	71.6	94.6	144.4	189.9
EXCHANGE (GAINS)/LOSSES	14.9	(16.3)	7.1	(23.4)
MINORITY INTERESTS	36.8	40.6	76.4	92.4
AMORTIZATION OF INTANGIBLES	37.2	36.9	74.5	68.2
Other, net	(22.1)	(195.4)	(339.1)	(231.5)
<b>TOTAL</b>	<b>\$ 69.9</b>	<b>\$ (121.8)</b>	<b>\$ (170.9)</b>	<b>\$ (74.0)</b>

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	2Q `04	2Q `03	YTD 2004	YTD 2003
IVOMEK, HEARTGARD, other avermectins	\$ 103	\$ 115	\$ 197	\$ 212
FRONTLINE	184	171	345	303
Biologicals	110	98	223	200
Other Animal Health	58	50	109	96
Poultry Breeding	36	37	71	75
<b>TOTAL MERIAL SALES</b>	<b>\$ 491</b>	<b>\$ 470</b>	<b>\$ 945</b>	<b>\$ 887</b>

<b>Aventis Pasteur-MSD</b>	2Q `04	2Q `03	YTD 2004	YTD 2003
HEPATITIS VACCINES	\$ 21	\$ 19	\$ 41	\$ 37
VIRAL VACCINES	14	13	27	24
Other Vaccines	125	114	245	204
<b>TOTAL AP-MSD SALES</b>	<b>\$ 159</b>	<b>\$ 146</b>	<b>\$ 313</b>	<b>\$ 265</b>

<b>Merck / Schering-Plough Collaboration</b>	2Q `04	2Q `03	YTD 2004	YTD 2003
VYTORIN (Worldwide)	\$ 5	\$ -	\$ 5	\$ -
ZETIA (Worldwide)	\$ 242	\$ 123	\$ 432	\$ 169
<b>TOTAL</b>	<b>\$ 247</b>	<b>\$ 123</b>	<b>\$ 437</b>	<b>\$ 169</b>